Evidence map›Paper›PMID 39570461›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Streptococcus pneumoniae and influenza vaccination rates in oncological patients - data from Germany.

Emma Niederstein, Journey Underwood, Maike de Wit, Mark Reinwald, Sandra Schwarzlose-Schwarck, Werner Dammermann, P Markus Deckert, Til Ramón Kiderlen

Abstract read
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Genomic characterization of invasiveMicrobial genomics · 2026
    Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Emma NiedersteinFaculty of Medicine and Psychology, Brandenburg Medical School Theodor Fontane, 14770, Brandenburg an der Havel, Germany. emma.niederstein@mhb-fontane.de.
Journey UnderwoodFaculty of Medicine and Psychology, Brandenburg Medical School Theodor Fontane, 14770, Brandenburg an der Havel, Germany.
Maike de WitDepartment of Hematology, Oncology and Palliative Care, Vivantes Hospital Neukoelln, 12351, Berlin, Germany.
Mark ReinwaldFaculty of Medicine and Psychology, Brandenburg Medical School Theodor Fontane, 14770, Brandenburg an der Havel, Germany.
Sandra Schwarzlose-SchwarckFaculty of Medicine and Psychology, Brandenburg Medical School Theodor Fontane, 14770, Brandenburg an der Havel, Germany.
Werner DammermannFaculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, 14770, Brandenburg an der Havel, Germany.
P Markus DeckertFaculty of Medicine and Psychology, Brandenburg Medical School Theodor Fontane, 14770, Brandenburg an der Havel, Germany.
Til Ramón KiderlenDepartment of Oncology, Vivantes Auguste-Viktoria-Hospital, 12157, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesDue to disease- or therapy-associated immunosuppression, oncological patients suffer from significantly higher morbidity and mortality due to infections transmitted by respiratory pathogens such as Streptococcus pneumoniae and influenza virus. Although the German Standing Committee on Vaccination (STIKO) provides specific recommendations for vaccination against these pathogens, there is no data on vaccination rates in this high-risk population.

methodsData from the interventional EVO study were analyzed to provide information on vaccination rates against Streptococcus pneumoniae and influenza virus in oncological patients. Numbers presented in this publication summarize baseline and follow-up data of the control group; thus, data were not influenced by the intervention.

resultsData of 370 patients were analyzed; 20.5% of patients were treated for hematological malignancies and 79.5% for solid cancer. 28.1% of patients had received vaccination against influenza and 32.2% against Streptococcus pneumoniae; for the latter only 7.3% according recommendations. While vaccination rates where even lower for patients with thoracic carcinoma (influenza 26.7% and Streptococcus pneumoniae 6.0% according to STIKO recommendations), rates in patients with multiple myeloma were remarkably higher (39.0% and 14.6%).

conclusionsDespite strong recommendations to vaccinate and the clear clinical need to prevent infections in the vulnerable group of oncological patients, only the minority was vaccinated against Streptococcus pneumoniae or influenza, underlining the urgent need for better vaccination strategies in this high-risk population.

Indexed as

Influenza, HumanInfluenza VaccinesNeoplasmsPneumococcal InfectionsPneumococcal VaccinesVaccinationAdultAgedAged, 80 and overFemaleGermanyHumansImmunocompromised HostMaleMiddle AgedStreptococcus pneumoniaeInfluenza VaccinesPneumococcal VaccinesCancer patientsHematologyImmunosuppressionInfluenzaOncologyStreptococcus pneumoniaeVaccination rates

Identifiers

PMID39570461
PMCPMC11582192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.